Evaluating the NFPp10a/NF5310 glioblastoma model as a clinically faithful syngeneic avatar for screening tumour microenvironment–targeted therapies

Résumé fourni par la source

Clinical trial failure in neuro-oncology is partly rooted in the poor translational reliability of current preclinical models. Here, we validate the NFPp10a/NF5310 syngeneic mouse model of GBM as a clinically relevant platform for evaluating tumour microenvironment (TME)-targeted therapies, including anti-PD1 checkpoint blockade and regorafenib. NFPp10a/NF5310 tumours exhibited resistance to both therapies, mirroring clinical response patterns. Hypothesis generating immune and transcriptomic profiling studies suggest modest T-cell recruitment and persistent T-cell exhaustion which are hallmarks of human GBM. Nevertheless, transcriptomic profiling further suggests conserved CD8⁺ T-cell phenotypes but reduced M2-like macrophage enrichment. These findings position NFPp10a/NF5310 as a translationally faithful model for testing select TME targeting agents. Our study highlights the critical requirement for target- and mechanism-informed model selection in preclinical GBM research.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.